Joy Hsu

2.6k total citations · 1 hit paper
16 papers, 1.0k citations indexed

About

Joy Hsu is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joy Hsu has authored 16 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Immunology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joy Hsu's work include Lung Cancer Treatments and Mutations (6 papers), Cancer Genomics and Diagnostics (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Joy Hsu is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer Genomics and Diagnostics (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Joy Hsu collaborates with scholars based in United States, Switzerland and United Kingdom. Joy Hsu's co-authors include Troy N. Trevino, David H. Raulet, Lily Zhang, Thornton W. Thompson, Karen Jardine, Jonathan J. Hodgins, Michele Ardolino, Alexandre Iannello, John C. Bell and Haley E. Randolph and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Joy Hsu

16 papers receiving 992 citations

Hit Papers

Contribution of NK cells to immunotherapy mediated by PD-... 2018 2026 2020 2023 2018 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
    2018 609 citations Joy Hsu, Jonathan J. Hodgins et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joy Hsu United States 8 731 581 214 100 65 16 1.0k
James Strauss United States 14 370 0.5× 394 0.7× 224 1.0× 88 0.9× 28 0.4× 69 837
Minish Jain United States 14 275 0.4× 459 0.8× 258 1.2× 155 1.6× 61 0.9× 68 828
Aleksandar Obradović United States 13 541 0.7× 311 0.5× 266 1.2× 171 1.7× 49 0.8× 38 895
Rodney A. Prell United States 15 1.0k 1.4× 563 1.0× 220 1.0× 48 0.5× 20 0.3× 24 1.3k
Adam Mor United States 16 421 0.6× 423 0.7× 263 1.2× 102 1.0× 51 0.8× 45 929
Ilia N. Buhtoiarov United States 15 614 0.8× 409 0.7× 164 0.8× 36 0.4× 31 0.5× 30 812
Michio Naoe Japan 11 387 0.5× 308 0.5× 265 1.2× 108 1.1× 17 0.3× 29 762
Sara Najmeh Canada 13 572 0.8× 213 0.4× 192 0.9× 210 2.1× 18 0.3× 36 916
Chrysoula I. Liakou United States 7 567 0.8× 639 1.1× 126 0.6× 94 0.9× 97 1.5× 10 866
Camillus Chua Singapore 13 460 0.6× 384 0.7× 205 1.0× 118 1.2× 50 0.8× 18 995

Countries citing papers authored by Joy Hsu

Since Specialization
Citations

This map shows the geographic impact of Joy Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joy Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joy Hsu more than expected).

Fields of papers citing papers by Joy Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joy Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joy Hsu. The network helps show where Joy Hsu may publish in the future.

Co-authorship network of co-authors of Joy Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Joy Hsu. A scholar is included among the top collaborators of Joy Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joy Hsu. Joy Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Hsu, Joy, et al.. (2024). Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity. Viruses. 16(6). 870–870. 5 indexed citations
2.
Marchand, Mathilde, Xiaoyan Liu, Gladys S. Ingle, et al.. (2022). Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation. The Journal of Clinical Pharmacology. 62(11). 1393–1402. 5 indexed citations
3.
Hsu, Joy, Elena Guerini, Bogdana Balas, et al.. (2021). Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer. CPT Pharmacometrics & Systems Pharmacology. 10(11). 1357–1370. 8 indexed citations
4.
Shemesh, Colby S., Joy Hsu, Iraj Hosseini, et al.. (2020). Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. Molecular Therapy. 29(2). 555–570. 188 indexed citations
5.
Hsu, Joy, Wendy Douglass, Chris Wells, et al.. (2019). Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatric Rheumatology. 17(1). 57–57. 19 indexed citations
6.
Adams, Nicholas M., Clair D. Geary, Endi K. Santosa, et al.. (2019). Cytomegalovirus Infection Drives Avidity Selection of Natural Killer Cells. Immunity. 50(6). 1381–1390.e5. 46 indexed citations
7.
Sostelly, Alexandre, Antoine Soubret, Barbara Klughammer, et al.. (2019). Exposure-Response Relationship of the SMART-Ig Anti-hC5 Antibody Crovalimab (SKY59): Results from the Umbrella Phase 1/2 Composer Trial in Healthy Volunteers and PNH Patients. Blood. 134(Supplement_1). 3745–3745. 4 indexed citations
8.
Smart, Kevin, Joy Hsu, Elena Guerini, et al.. (2019). Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies.. Journal of Clinical Oncology. 37(15_suppl). e20575–e20575. 3 indexed citations
9.
Morcos, Peter N., Elena Guerini, Joy Hsu, et al.. (2018). Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 82(1). 129–138. 24 indexed citations
10.
Hsu, Joy, Jonathan J. Hodgins, Marie‐Claude Bourgeois‐Daigneault, et al.. (2018). Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. Journal of Clinical Investigation. 128(10). 4654–4668. 609 indexed citations breakdown →
11.
Hsu, Joy, Alice T. Shaw, Caicun Zhou, et al.. (2018). Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population.. Journal of Clinical Oncology. 36(15_suppl). e21133–e21133. 1 indexed citations
12.
Meneses‐Lorente, Georgina, Christine McIntyre, Joy Hsu, et al.. (2017). Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab. Cancer Chemotherapy and Pharmacology. 79(6). 1239–1247. 3 indexed citations
13.
Hsu, Joy, Elena Guerini, Tomohiro Tanaka, et al.. (2017). Population pharmacokinetics (popPK) and exposure-response (ER) analyses bridge J-ALEX to the global population with an alectinib (ALC) 600mg bid dosing regimen.. Journal of Clinical Oncology. 35(15_suppl). e20616–e20616. 5 indexed citations
14.
Benedetti, Fabrizio De, Nicolino Ruperto, Daniel J. Lovell, et al.. (2017). THU0503 Identification of optimal subcutaneous (SC) doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis (PCJIA). Annals of the Rheumatic Diseases. 76. 396–396. 2 indexed citations
15.
Abdallah, Hisham, Joy Hsu, Peng Lü, et al.. (2016). Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. The Journal of Clinical Pharmacology. 57(4). 459–468. 70 indexed citations
16.
Hsu, Joy, Volkmar Henschel, Katrijn Bogman, et al.. (2016). Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population.. Journal of Clinical Oncology. 34(15_suppl). e20598–e20598. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James Strauss Breakdown of academic impact, for papers by Minish Jain Breakdown of academic impact, for papers by Aleksandar Obradović Breakdown of academic impact, for papers by Rodney A. Prell Breakdown of academic impact, for papers by Adam Mor Breakdown of academic impact, for papers by Ilia N. Buhtoiarov Breakdown of academic impact, for papers by Michio Naoe Breakdown of academic impact, for papers by Sara Najmeh Breakdown of academic impact, for papers by Chrysoula I. Liakou Breakdown of academic impact, for papers by Camillus Chua
Rankless by CCL
2026